Pazopanib · Votrient

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Renal Cell Carcinoma, Soft Tissue Sarcoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
EU
  • Renal-cell carcinoma (RCC) Votrient is indicated in adults for the first-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease. Soft-tissue sarcoma (STS) Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy. Efficacy and safety have only been established in certain STS histological tumour subtypes.
Product first approved 2010EMA
CA
  • Metastatic Renal Cell Carcinoma VOTRIENT (pazopanib hydrochloride) is indicated for the treatment of patients with metastatic renal cell (clear cell) carcinoma (mRCC) as first-line systemic therapy or as second-line systemic therapy after treatment with cytokines for metastatic disease. Approval of VOTRIENT in mRCC is based on significant progression-free survival benefit in patients with mRCC of good performance status (ECOG 0-1). Prolongation of overall survival was not demonstrated nor were quality-of-life differences shown between patients receiving VOTRIENT versus placebo in the...
Product first approved 2010Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (9)
Renal Cell Carcinoma
NCT01575548 · National Cancer Institute (NCI)
2012-08-08 – 2027-02-20 · Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
What this study did
Soft Tissue Sarcoma
Other / comorbidity
NCT01064310 · Novartis Pharmaceuticals
2010-05-17 – 2015-11-23 · Carcinoma, Renal Cell
What this study did
Phase 2/3 (4)
Soft Tissue Sarcoma
NCT02180867 · National Cancer Institute (NCI)
2014-08-12 – 2026-03-31 · Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma, Clear Cell Sarcoma of Soft Tissue, Epithelioid Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Extraskeletal Osteosarcoma, Fibrohistiocytic Neoplasm, Fibrosarcoma, Inflammatory Myofibroblastic Tumor, Intimal Sarcoma, Leiomyosarcoma, Liposarcoma, Liver Embryonal Sarcoma, Low Grade Fibromyxoid Sarcoma, Low Grade Myofibroblastic Sarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Skin Granular Cell Tumor, Malignant Triton Tumor, Mesenchymal Chondrosarcoma, Myxofibrosarcoma, Myxoid Chondrosarcoma, Myxoinflammatory Fibroblastic Sarcoma, Nerve Sheath Neoplasm, PEComa, Pericytic Neoplasm, Plexiform Fibrohistiocytic Tumor, Sclerosing Epithelioid Fibrosarcoma, Skin Glomus Tumor, Stage IB Soft Tissue Sarcoma AJCC v7, Stage IIB Soft Tissue Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone
What this study did
Other / comorbidity
NCT03850964 · Cure HHT
2023-05-08 – 2026-08-26 · Hereditary Hemorrhagic Telangiectasia, Epistaxis, Anemia, Nosebleed, HHT
What this study did
NCT00775307 · Intergroupe Francophone de Cancerologie Thoracique
2008-11 – 2016-04-18 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT01208064 · European Organisation for Research and Treatment of Cancer - EORTC
2011-07 – 2015-06 · Lung Cancer
What this study did
Phase 2 (128)
Renal Cell Carcinoma
NCT01217931 · M.D. Anderson Cancer Center
2011-01-19 – 2028-01-31 · Kidney Cancer
What this study did
NCT01147822 · Novartis Pharmaceuticals
2010-05-19 – 2021-09-03 · Carcinoma, Renal Cell
What this study did
NCT03200717 · Novartis Pharmaceuticals
2017-11-14 – 2021-08-10 · Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
What this study did
NCT02960906 · Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
2017-05-31 – 2021-02-15 · Clear Cell Metastatic Renal Cell Carcinoma
What this study did
NCT01767636 · Mayo Clinic
2013-05-16 – 2021-01-20 · Carcinoma of the Collecting Ducts of Bellini, Chromophobe Renal Cell Carcinoma, Kidney Medullary Carcinoma, Kidney Oncocytoma, Metastatic Renal Cell Cancer, Papillary Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage IV Renal Cell Cancer
What this study did
NCT01664182 · National Cancer Institute (NCI)
2012-08-01 – 2020-12-07 · Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
What this study did
NCT01566747 · Cancer Trials Ireland
2011-03 – 2020-07-15 · Renal Cell Carcinoma
What this study did
NCT01392183 · M.D. Anderson Cancer Center
2012-10-24 – 2019-09-08 · Kidney Cancer
What this study did
NCT01361113 · UNC Lineberger Comprehensive Cancer Center
2011-06 – 2017-02-15 · Renal Cell Carcinoma
What this study did
NCT04462445 · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
2015-06-25 – 2017-02-08 · Metastatic Renal Cell Carcinoma
What this study did
NCT01545817 · Novartis Pharmaceuticals
2012-04-19 – 2016-11-18 · Carcinoma, Renal Cell
What this study did
NCT01731158 · Central European Society for Anticancer Drug Research
2012-10 – 2016-09 · Metastatic Renal Cell Carcinoma
What this study did
NCT02089802 · Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.
2014-02-25 – 2016-03-22 · Locally Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
What this study did
NCT01158521 · Case Comprehensive Cancer Center
2010-06 – 2016-01 · Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer
What this study did
NCT01538238 · Samsung Medical Center
2012-05-02 – 2015-11-14 · Locally Advanced or Metastatic Non-clear Cell Type Renal Cell Carcinoma
What this study did
NCT01577784 · Associació per a la Recerca Oncologica, Spain
2012-04 – 2015-10 · Metastatic Renal Cell Carcinoma
What this study did
NCT01392352 · Cambridge University Hospitals NHS Foundation Trust
2011-04 – 2015-09 · Renal Cell Carcinoma, Soft Tissue Sarcoma, Glioblastoma, Ovarian Cancer, Cervical Cancer, Breast Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Pancreatic Cancer, Melanoma, Gastrointestinal Cancer
What this study did
NCT01157091 · City of Hope Medical Center
2010-12-08 – 2013-12-31 · Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
What this study did
NCT00244764 · GlaxoSmithKline
Run by former owner GlaxoSmithKline
2005-10 – 2013-09 · Carcinoma, Renal Cell
What this study did
NCT00731211 · SCRI Development Innovations, LLC
2008-09 – 2012-09 · Renal Cell Carcinoma
What this study did
Soft Tissue Sarcoma
NCT05679921 · Yonsei University
2024-03-01 – 2026-12-31 · Soft Tissue Sarcoma
What this study did
NCT03798106 · Yonsei University
2019-04-10 – 2022-08-10 · Sarcoma
What this study did
NCT03149120 · NYU Langone Health
2017-08 – 2022-06 · Soft Tissue Sarcomas
What this study did
NCT02357810 · Northwestern University
2015-03-21 – 2021-10-12 · Adult Liposarcoma, Metastatic Liposarcoma, Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Liposarcoma, Recurrent Osteosarcoma, Stage IV Adult Soft Tissue Sarcoma
What this study did
NCT01462630 · Fox Chase Cancer Center
2011-11-03 – 2021-01-12 · Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
What this study did
NCT02300545 · Washington University School of Medicine
2015-04-08 – 2020-07-11 · Sarcoma, Soft Tissue, Soft Tissue Sarcoma
What this study did
NCT01532687 · OHSU Knight Cancer Institute
2012-03-13 – 2019-10-31 · Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Peripheral Nerve Sheath Tumor, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Adult Undifferentiated Pleomorphic Sarcoma, Malignant Adult Hemangiopericytoma, Recurrent Adult Soft Tissue Sarcoma, Sarcoma, Stage III Adult Soft Tissue Sarcoma AJCC v7, Stage IV Adult Soft Tissue Sarcoma AJCC v7
What this study did
NCT01593748 · Medical University of South Carolina
2012-09-27 – 2019-04-24 · Sarcoma
What this study did
NCT02575066 · The Netherlands Cancer Institute
2016-03-17 – 2019-03-20 · Sarcoma, Soft Tissue Sarcomas
What this study did
NCT02367651 · GlaxoSmithKline
Run by former owner GlaxoSmithKline
2015-06 – 2018-05 · Sarcoma, Soft Tissue
What this study did
NCT01861951 · Hannover Medical School
2012-10 – 2017-07-11 · Soft Tissue Sarcoma
What this study did
NCT01543802 · Heidelberg University
2013-04 – 2016-10 · Sarcoma, Soft-tissue
What this study did
NCT00297258 · GlaxoSmithKline
Run by former owner GlaxoSmithKline
2005-11 – 2014-02 · Sarcoma, Soft Tissue
What this study did
Other / comorbidity
NCT02029001 · Centre Leon Berard
2014-03 – 2028-10 · Malignant Solid Neoplasms
What this study did
NCT01841736 · National Cancer Institute (NCI)
2013-09-20 – 2027-09-10 · Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Neuroendocrine Tumor, Midgut Neuroendocrine Tumor G1, Neuroendocrine Tumor G2, Recurrent Digestive System Neuroendocrine Tumor G1, Regional Digestive System Neuroendocrine Tumor G1
What this study did
NCT06739395 · Tianjin Medical University Second Hospital
2024-11-01 – 2027-05-01 · Solid Tumor, Precision Medicine
What this study did
NCT06816771 · Shandong Cancer Hospital and Institute
2025-02 – 2026-12-31 · Rhabdomyosarcoma, Recurrent, Refractory
What this study did
NCT02203760 · North Eastern German Society of Gynaecological Oncology
2019-10-16 – 2024-12-31 · Leiomyosarcoma or Carcinosarcoma
What this study did
NCT01436227 · M.D. Anderson Cancer Center
2012-01-17 – 2024-03-13 · Von Hippel-Lindau Syndrome
What this study did
NCT02638428 · Samsung Medical Center
2015-12 – 2023-12 · Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor, Relapsed Pediatric AML, Refractory Pediatric AML
What this study did
NCT02066285 · Grupo Espanol de Investigacion en Sarcomas
2014-06 – 2023-03-24 · Solitary Fibrous Tumor, Extraskeletal Myxoid Chondrosarcoma
What this study did
NCT01236547 · National Cancer Institute (NCI)
2010-10-28 – 2022-05-20 · Thyroid Gland Anaplastic Carcinoma
What this study did
NCT01610206 · Linda R Duska
2012-09 – 2020-12-31 · Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
What this study did
NCT02383251 · ARCAGY/ GINECO GROUP
2015-06-15 – 2020-12-31 · Ovarian Cancer
What this study did
NCT02212015 · Heidelberg University
2014-07 – 2020-07-01 · Angiosarcoma
What this study did
NCT02342600 · Sarcoma Alliance for Research through Collaboration
2017-01 – 2020-01 · Gastrointestinal Stromal Tumors
What this study did
NCT02193152 · Washington University School of Medicine
2015-04-27 – 2019-12-24 · Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
What this study did
NCT01956669 · Novartis Pharmaceuticals
2014-10-08 – 2019-11-05 · Solid Tumours
What this study did
NCT01466972 · Hope Rugo, MD
2012-04-27 – 2019-10-02 · Breast Cancer, Breast Neoplasm
What this study did
NCT02393820 · UNICANCER
2013-08-26 – 2019-10 · Salivary Gland Carcinoma
What this study did
Phase 1/2 (23)
Renal Cell Carcinoma
NCT01684397 · Roswell Park Cancer Institute
2012-11-21 – 2027-02-20 · Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer
What this study did
NCT01513187 · Spanish Oncology Genito-Urinary Group
2011-07-11 – 2019-02-22 · Advanced Renal Cell Carcinoma
What this study did
Soft Tissue Sarcoma
NCT06239272 · St. Jude Children's Research Hospital
2024-03-27 – 2037-06 · Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma, Angiomatoid Fibrous Histiocytoma, Fibrosarcoma NOS, Myxofibrosarcoma, Angiosarcoma, Osteosarcoma, Extraskeletal, Dedifferentiated Liposarcoma, Myxoid Liposarcoma, Pleomorphic Liposarcoma, Myxoid Pleomorphic Liposarcoma, Low Grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, Malignant Tenosynovial Giant Cell Tumor of Soft Tissue, Epithelioid Hemangioendothelioma, Glomus Tumor, Inflammatory Leiomyosarcoma, Leiomyosarcoma, Ossifying Fibromyxoid Tumor, Malignant, Myoepithelioma, Synovial Sarcoma, Epithelioid Sarcoma, Perineurioma, Malignant, Clear Cell Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Granular Cell Tumor, Malignant, Melanotic Malignant Nerve Sheath Tumor, Malignant Peripheral Nerve Sheath Tumor, Perivascular Epithelioid Tumor, Malignant, Intimal Sarcoma, Myoepithelial Carcinoma, Undifferentiated Sarcoma, Pleomorphic Sarcoma, Undifferentiated, Round Cell Sarcoma, Undifferentiated, NTRK-Rearranged Spindle Cell Neoplasm, Phosphaturic Mesenchymal Tumor, Malignant, Round Cell Sarcoma, Well Differentiated Liposarcoma, Giant Cell Tumor of Soft Parts NOS, Low Grade Myofibroblastic Sarcoma, Dermatofibrosarcoma Protuberans, Fibrosarcomatous
What this study did
NCT05180695 · Centre Leon Berard
2022-04-15 – 2027-02 · Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma
What this study did
NCT03660930 · University of Washington
2019-04-01 – 2024-07-31 · Advanced Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma
What this study did
NCT01975519 · Tracon Pharmaceuticals Inc.
2013-12-10 – 2019-03-11 · Advanced Soft Tissue Sarcoma
What this study did
NCT01418001 · Memorial Sloan Kettering Cancer Center
2011-08 – 2015-11 · Sarcoma, Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Fibrous, Histiocytoma/Undifferentiated Pleomorphic Sarcoma
What this study did
NCT01719302 · University of Vermont
2012-10 – 2015-04 · Stage III Adult Soft Tissue Sarcoma
What this study did
Other / comorbidity
NCT02331498 · Centre Antoine Lacassagne
2015-06 – 2030-08 · Glioblastoma Multiforme
What this study did
NCT05210413 · University Hospital, Bordeaux
2022-05-17 – 2027-11-17 · Refractory or Recurrent Solid Tumor
What this study did
NCT03850730 · Cure HHT
2023-07-01 – 2025-12-31 · Hereditary Hemorrhagic Telangiectasia, Epistaxis
What this study did
NCT06895733 · Tianjin Medical University Second Hospital
2024-11-27 – 2025-12-31 · Solid Tumor, Adult, Next-generation Sequencing, Precision Medicine
What this study did
NCT03628131 · Samsung Medical Center
2018-10 – 2025-07 · Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor
What this study did
NCT02601209 · National Cancer Institute (NCI)
2015-11-30 – 2022-07-11 · High Grade Sarcoma, Metastatic Leiomyosarcoma, Metastatic Malignant Peripheral Nerve Sheath Tumor, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Metastatic Unresectable Sarcoma, Myxofibrosarcoma, Recurrent Leiomyosarcoma, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Synovial Sarcoma, Recurrent Undifferentiated Pleomorphic Sarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Leiomyosarcoma
What this study did
NCT02303028 · The Hospital for Sick Children
2015-03 – 2022-06-17 · Solid Tumors
What this study did
NCT01465659 · Northwestern University
2011-12-12 – 2021-01-27 · Pancreatic Alpha Cell Carcinoma, Pancreatic Beta Islet Cell Carcinoma, Pancreatic Delta Cell Carcinoma, Pancreatic G-cell Carcinoma, Recurrent Islet Cell Carcinoma
What this study did
NCT01402271 · European Organisation for Research and Treatment of Cancer - EORTC
2012-07 – 2020-07-13 · Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
What this study did
NCT01600573 · JSehouli
2012-05 – 2017-03 · Ovarian Cancer
What this study did
NCT01238770 · Priv.-Doz. Dr. med. Joachim Rom
2010-11 – 2015-10 · Epithelial Ovarian Cancer
What this study did
NCT01716546 · Hellenic Oncology Research Group
2011-07 – 2015-01 · Gastric Cancer
What this study did
NCT01035658 · SCRI Development Innovations, LLC
2010-01 – 2014-03 · Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma
What this study did
NCT01265940 · Prof. Dr. Thomas Otto
2011-03 – 2012-08 · Advanced Urothelial Cancer of Bladder After Failure of Platinum-containing Therapy.
What this study did
NCT01257750 · Reza Dana, MD
2010-11 – 2012-01 · Corneal Neovascularization
What this study did
Phase 1 (68)
Renal Cell Carcinoma
NCT02009449 · Eli Lilly and Company
2013-11-15 – 2023-07-22 · Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer
What this study did
NCT01472081 · Bristol-Myers Squibb
2012-02-09 – 2021-06-03 · Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma
What this study did
NCT02406521 · Dana-Farber Cancer Institute
2015-04 – 2019-12-31 · Metastatic Renal Cell Carcinoma
What this study did
NCT01221506 · Abramson Cancer Center at Penn Medicine
2010-10 – 2019-04 · Carcinoma, Renal Cell
What this study did
NCT02795819 · Virginia Commonwealth University
2016-07-08 – 2019-03-14 · Renal Cell Carcinoma, Soft Tissue Sarcoma, Metastatic Disease
What this study did
NCT02014636 · Novartis Pharmaceuticals
2013-12-27 – 2019-02-27 · Carcinoma, Renal Cell
What this study did
NCT02729194 · University of Michigan Rogel Cancer Center
2016-06 – 2017-09 · Carcinoma, Renal Cell
What this study did
NCT00992121 · GlaxoSmithKline
Run by former owner GlaxoSmithKline
2009-11-18 – 2013-11-01 · Carcinoma, Renal Cell
What this study did
NCT01202032 · Centre Leon Berard
2010-07 – 2013-03 · Metastatic Renal Cell Carcinoma, Advanced Refractory Solid Tumors Histologically or Cytologically Confirmed
What this study did
Soft Tissue Sarcoma
NCT07444619 · M.D. Anderson Cancer Center
2026-06-12 – 2033-12-31 · Soft Tissue Sarcomas
What this study did
NCT01438554 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2011-10 – 2018-08 · Solid Tumors, Thyroid Cancer, Soft-tissue Sarcoma, Cholangiocarcinoma
What this study did
NCT00929903 · National Cancer Institute (NCI)
2009-06 – 2013-04 · Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Metastatic Childhood Soft Tissue Sarcoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Central Nervous System Embryonal Tumor, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Visual Pathway Glioma, Unspecified Childhood Solid Tumor, Protocol Specific
What this study did
Other / comorbidity
NCT01552356 · National Cancer Institute (NCI)
2012-03-19 – 2027-03-31 · Solid Neoplasm
What this study did
NCT01543763 · Pamela Munster
2012-06-25 – 2024-12-31 · Metastatic Solid Tumors
What this study did
NCT01548144 · M.D. Anderson Cancer Center
2012-04 – 2021-08-26 · Advanced Cancers
What this study did
NCT03139331 · University of California, San Francisco
2017-06-06 – 2020-09-30 · Sarcoma, Refractory Sarcoma
What this study did
NCT01430572 · M.D. Anderson Cancer Center
2011-10-07 – 2020-05-12 · Advanced Cancers, Solid Tumors
What this study did
NCT01713972 · Manisha Shah
2012-11-19 – 2018-12-26 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT02138526 · Radboud University Medical Center
2014-06 – 2018-11 · Cancer
What this study did
NCT03275558 · Center Trials & Treatment
2018-07-17 – 2018-07-17 · Recurrent Glioblastoma, Gliosarcoma, Anaplastic Gliomas
What this study did
NCT00387205 · Novartis Pharmaceuticals
2006-06-20 – 2018-03-08 · Carcinoma, Renal Cell
What this study did
NCT01642017 · Institut Claudius Regaud
2012-11-22 – 2018-03 · Metastatic Cancer (Different Solid Tumour Types)
What this study did
NCT01716416 · Washington University School of Medicine
2013-05-31 – 2017-08-31 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT02810756 · The Netherlands Cancer Institute
2016-09-15 – 2017-08-28 · Pharmacokinetics of Pazopanib
What this study did
NCT01339871 · M.D. Anderson Cancer Center
2011-04-20 – 2017-06-07 · Advanced Cancer
What this study did
NCT01184326 · Dana-Farber Cancer Institute
2011-01 – 2017-03 · Solid Tumor, Kidney Cancer
What this study did
NCT01639911 · University of Illinois at Chicago
2013-08-14 – 2016-07-28 · Malignant Neoplasm of Breast, CNS Malignancy, Malignant Neoplasm of Gastrointestinal Tract, Genitourinary Neoplasms Malignancy and Gender Unspecified, Head and Neck Neoplasms, Melanoma, Malignant Neoplasm of Thorax
What this study did
NCT01608009 · Imperial College London
2012-07 – 2016-04 · Ovarian Neoplasm
What this study did
NCT01407562 · Rutgers, The State University of New Jersey
2010-09-17 – 2016-03-29 · Unspecified Adult Solid Tumor - Protocol Specific, Breast Cancer - Female
What this study did
NCT01468922 · National Cancer Institute (NCI)
2012-01-23 – 2016-02-11 · Solid Tumor
What this study did
NCT01385228 · Daniel George, MD
2011-06 – 2016-02 · Prostate Cancer
What this study did
NCT00516672 · GlaxoSmithKline
Run by former owner GlaxoSmithKline
2007-09-10 – 2015-10-14 · Carcinoma, Renal Cell
What this study did
NCT01413113 · University of Washington
2011-12 – 2015-10 · Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer, Stage IVB Papillary Thyroid Cancer, Stage IVC Follicular Thyroid Cancer, Stage IVC Papillary Thyroid Cancer
What this study did
NCT00800345 · Vector Oncology
2009-04 – 2015-09 · Gynecologic Tumors
What this study did
NCT00788580 · SWOG Cancer Research Network
— · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT01454804 · M.D. Anderson Cancer Center
2011-10 – 2015-03 · Advanced Cancers
What this study did
NCT01985295 · The Netherlands Cancer Institute
2010-06 – 2014-11 · Sarcoma,Soft Tissue
What this study did
NCT01165385 · UNICANCER
2010-06 – 2014-10 · Solid Tumors, Metastatic Cancer
What this study did
NCT01498458 · GBG Forschungs GmbH
2010-10 – 2014-05 · Metastatic Breast Cancer
What this study did
NCT01485042 · Herbert Hurwitz, MD
2011-12 – 2014-03 · Solid Tumors
What this study did
NCT00722293 · GlaxoSmithKline
Run by former owner GlaxoSmithKline
2008-07-08 – 2014-02-25 · Neoplasms, Breast
What this study did
NCT01060514 · Northwestern University
2010-02 – 2013-09 · Metastatic Non Small Cell Lung Cancer, Metastatic Breast Cancer
What this study did
NCT01542047 · New Mexico Cancer Research Alliance
2012-08 – 2013-07 · Cancer, Metastatic
What this study did
NCT00732420 · GlaxoSmithKline
Run by former owner GlaxoSmithKline
2008-09-24 – 2013-06-12 · Solid Tumours
What this study did
NCT01012362 · Masonic Cancer Center, University of Minnesota
2009-12 – 2013-02 · Breast Cancer, Lung Cancer, Colon Cancer, Pancreatic Cancer, Head and Neck Cancer, Kidney Cancer, Sarcoma, Hepatocellular Cancer
What this study did
NCT00674024 · National Cancer Institute (NCI)
2008-10-07 – 2013-01-22 · Neoplasms, Lymphoma
What this study did
NCT00866528 · GlaxoSmithKline
Run by former owner GlaxoSmithKline
2009-07-09 – 2012-10-25 · Lung Cancer, Non-Small Cell
What this study did
NCT01072890 · University of California, Davis
2010-02 – 2012-02 · Solid Tumors
What this study did
NCT01130623 · National Cancer Institute (NCI)
2010-05-10 – 2011-11-18 · Sarcoma, Neuroblastoma, Wilms Tumor, Osteosarcoma, Brain Tumor
What this study did
NCT00450879 · National Cancer Institute (NCI)
2007-01 – 2011-09 · Male Breast Carcinoma, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
What this study did
Phase 4 (6)
Renal Cell Carcinoma
NCT05949424 · University Medical Center Groningen
2024-05 – 2025-03 · Renal Cell Carcinoma, Ovarian Carcinoma, Thyroid Carcinoma, Breast Carcinoma, Endometrium Carcinoma
What this study did
NCT02570789 · Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2012-12 – 2021-03-01 · Clear-cell Metastatic Renal Cell Carcinoma
What this study did
NCT02555748 · Institut Claudius Regaud
2015-11-17 – 2020-01-16 · Metastatic Renal Cell Cancer
What this study did
NCT01521715 · iOMEDICO AG
2012-01-24 – 2017-07-31 · Locally Advanced and/or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma
What this study did
Soft Tissue Sarcoma
NCT03735758 · GWT-TUD GmbH
2018-11-02 – 2020-10-06 · Soft Tissue Sarcoma Adult
What this study did
Other / comorbidity
NCT01205230 · GlaxoSmithKline
Run by former owner GlaxoSmithKline
2010-09 – 2011-08 · Cancer
What this study did
Early phase / not applicable (8)
Renal Cell Carcinoma
NCT02208128 · Heidelberg University
2014-05 – 2018-02 · Renal Cell Carcinoma
What this study did
NCT01599832 · University of Chicago
2012-06 – 2015-12 · Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
What this study did
NCT02307474 · Case Comprehensive Cancer Center
2015-09 – 2015-09 · Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma
What this study did
Soft Tissue Sarcoma
NCT01446809 · University of Washington
2012-04 – 2019-01 · Stage IIA Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
What this study did
Other / comorbidity
NCT04199026 · M.D. Anderson Cancer Center
2025-02-25 – 2028-12-31 · Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma
What this study did
NCT02691767 · Samsung Medical Center
2016-05 – 2020-02-13 · Refractory Solid Tumors
What this study did
NCT01636908 · Amsterdam UMC, location VUmc
2011-08 – 2019-12-01 · Cancer, Advanced Solid Tumors
What this study did
NCT02450136 · Samsung Medical Center
2015-10-08 – 2018-02 · Refractory Solid Tumors
What this study did
Used as active comparator (10)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (4)
Renal Cell Carcinoma
NCT03260894 · Incyte Corporation
2017-12-07 – 2025-06-04 · Renal Cell Carcinoma (RCC)
What this study did
Soft Tissue Sarcoma
NCT06263231 · Intensity Therapeutics, Inc.
2024-06-28 – 2028-12 · Sarcoma,Soft Tissue
What this study did
NCT02049905 · ImmunityBio, Inc.
2014-01 – 2017-05 · Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma
What this study did
Other / comorbidity
NCT04741438 · Centre Leon Berard
2021-03-30 – 2025-08 · Sarcoma
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT05432791 · National Cancer Institute (NCI)
2023-03-30 – 2027-01-30 · Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Uterine Corpus Leiomyosarcoma
What this study did
Phase 2 (3)
Renal Cell Carcinoma
Other / comorbidity
NCT00558103 · GlaxoSmithKline
Run by former owner GlaxoSmithKline
2007-12 – 2011-12 · Neoplasms, Breast
What this study did
NCT00430781 · GlaxoSmithKline
Run by former owner GlaxoSmithKline
2006-11 – 2011-07 · Neoplasms, Uterine Cervix, Metastatic Cervical Cancer
What this study did
Early phase / not applicable (2)
Renal Cell Carcinoma
NCT05816642 · RenJi Hospital
2022-08-01 – 2024-12-31 · Metastatic Renal Cell Carcinoma
What this study did
Other / comorbidity
NCT03571438 · University Hospital, Grenoble
2017-10-16 – 2024-09-30 · Kidney Cancer
What this study did
Appears in other studies (8)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (4)
Renal Cell Carcinoma
NCT06726421 · Sun Yat-sen University
2024-09-18 – 2033-09-30 · Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic
What this study did
NCT03592472 · Xynomic Pharmaceuticals, Inc.
2018-07-17 – 2028-06-30 · Renal Cell Carcinoma
What this study did
NCT02535351 · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
2015-11 – 2018-09-28 · Clear-cell Metastatic Renal Cell Carcinoma
What this study did
Other / comorbidity
NCT02979899 · Tracon Pharmaceuticals Inc.
2017-02-13 – 2019-08-31 · Advanced Angiosarcoma
What this study did
Phase 2 (3)
Renal Cell Carcinoma
NCT07087158 · Imbioray (Hangzhou) Biomedicine Co., Ltd.
2025-09-08 – 2026-12-31 · Renal Cell Carcinoma (RCC)
What this study did
NCT03334409 · Academic and Community Cancer Research United
2018-02-16 – 2021-03-13 · Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v7, Unresectable Renal Cell Carcinoma
What this study did
NCT03379012 · Kidney Cancer Research Bureau
2016-02-08 – 2019-07-30 · Metastatic Renal Cell Carcinoma
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT02055690 · The Christie NHS Foundation Trust
2014-09 – 2017-11-24 · Ovarian Neoplasms, Neoplasms, Ovarian, Ovarian Cancer
What this study did

Competitive landscape

Other Multi-kinase inhibitor (VEGFR/PDGFR/KIT) drugs

Regorafenib. Compare all 2 Multi-kinase inhibitor (VEGFR/PDGFR/KIT) drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Renal Cell Carcinoma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Pazopanib (Votrient): this drugApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)Reliable signalFeatured results are non-efficacy only in this race
Aldesleukin (Proleukin)ApprovedRecombinant Cytokine (il-2)Interleukin-2 receptor (IL-2R)not yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AvelumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
AxitinibApprovedSmall moleculeVEGFR1/2/3Partial signal
NCT02684006: Primaries in PD-L1-positive patients, avelumab + axitinib vs sunitinib: PFS (BICR) median 13.8 vs 7.2 months, hazard ratio 0.61 (95% CI 0.475 to 0.790), p=0.0001, met; OS median 43.2 vs 36.2 months, hazard ratio 0.86 (95% CI 0.701 to 1.057), p=0.1509, not significant (CT.gov posted results).
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Belzutifan (Welireg)ApprovedSmall moleculeHIF-2alphanot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
CabozantinibApprovedSmall moleculeMET / VEGFR / AXL / RET (multi-kinase)Partial signalNo reviewed efficacy summary in this indication
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01668784: Overall Survival (OS) at Primary Endpoint (Randomization until 398 deaths, up to May 2015 (approximately 30 months)): Nivolumab 25 months | Everolimus 19.55 months (95% CI 17.64 to 23.06)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02811861: Progression-free Survival (PFS) by Independent Imaging Review (IIR) (From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first or up to data cutoff date 28 Aug 2020 (up to approximately 46 months)): Lenvatinib 18 mg Plus Everolimus 5 mg 14.7 months (95% CI 11.1 to 16.7) | Lenvatinib 20 mg Plus Pembrolizumab 200 mg 23.9 months (95% CI 20.8 to 27.7) | Sunitinib 50 mg 9.2 months (95% CI 6 to 11)
NCT04704219: Objective Response Rate (ORR) (Up to approximately 47 months): Pembrolizumab + Lenvatinib 50.6 Percentage of participants (95% CI 42.6 to 58.7)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Regorafenib
Approved(overall)
Small moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)
Reliable signal(overall)
No reviewed efficacy summary in this indication
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
DurvalumabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Fruquintinib (Fruzaqla / Elunate)Phase 3Small moleculeVEGFR1/2/3not yet gradedNo reviewed efficacy summary in this indication
Savolitinib (Orpathys)Phase 3Small moleculeMETnot yet gradedNo reviewed efficacy summary in this indication
ZanzalintinibPhase 3Small moleculeVEGFR2; MET; AXL; MER; TYRO3not yet gradedNo reviewed efficacy summary in this indication
CiforadenantPhase 1/2Small moleculeadenosine A2Anot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(10 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Votrient (Pazopanib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 2Solid Tumor, Precision MedicineRecruiting
Est. primary completion 2026-12-31 · NCT06739395 · CT.gov ↗
What to watch
Phase 2Soft Tissue SarcomaRecruiting
Est. primary completion 2026-12-31 · NCT05679921 · CT.gov ↗
What to watch
2027 (3)
February 2027 (3)
Phase 1/2Glioblastoma MultiformeActive not recruiting
Est. primary completion 2027-02 · NCT02331498 · CT.gov ↗
What to watch
Phase 1/2Soft Tissue SarcomaActive not recruiting
Est. primary completion 2027-02 · NCT05180695 · CT.gov ↗
What to watch
Phase 1/2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-02-20 · NCT01684397 · CT.gov ↗
What to watch
2028 (3)
January 2028 (2)
Phase 2Malignant Solid NeoplasmsRecruiting
Est. primary completion 2028-01 · NCT02029001 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2028-01-31 · NCT01217931 · CT.gov ↗
What to watch
December 2028 (1)
Early phase / not applicableMetastatic Sarcoma, Recurrent Sarcoma, Resectable SarcomaRecruiting
Est. primary completion 2028-12-31 · NCT04199026 · CT.gov ↗
What to watch
2031 (1)
December 2031 (1)
Phase 1Soft Tissue SarcomaRecruiting
Est. primary completion 2031-12-31 · NCT07444619 · CT.gov ↗
What to watch
2034 (1)
June 2034 (1)
Phase 1/2Soft Tissue SarcomaRecruiting
Est. primary completion 2034-06 · NCT06239272 · CT.gov ↗
What to watch

See the full readout calendar ↗